Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trastuzumab in Treating Patients With Recurrent Osteosarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 6, 2000
Last updated: June 20, 2013
Last verified: August 2004

RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma.

Condition Intervention Phase
Biological: trastuzumab
Procedure: conventional surgery
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: December 1999
Study Completion Date: August 2004
Detailed Description:


  • Determine the response rate, freedom from progression, and survival of patients with recurrent osteosarcoma when treated with trastuzumab (Herceptin).
  • Evaluate the toxicity of this drug in young patients with a history of osteosarcoma and prior therapy with doxorubicin.

OUTLINE: This is a multicenter study.

Patients receive trastuzumab (Herceptin) IV over 30-90 minutes weekly. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity. After approximately 12 weeks of treatment, patients are evaluated for response and undergo surgical resection if clinically appropriate.

Patients are followed for 1 year for survival.

PROJECTED ACCRUAL: Approximately 20-40 patients will be accrued for this study within 2 years.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed recurrent osteosarcoma after initial systemic therapy with doxorubicin
  • Measurable disease
  • Immunohistochemical evidence of 2+ overexpression of HER2



  • Any age

Performance status:

  • Karnofsky 80-100%

Life expectancy:

  • Not specified


  • Not specified


  • ALT or AST less than 3 times upper limit of normal (ULN)
  • Bilirubin less than 1.5 times ULN


  • Creatinine less than 1.5 times ULN OR
  • Creatinine clearance greater than 60 mL/min


  • Fractional shortening at least 29% by echocardiogram OR
  • Ejection fraction at least 50% by MUGA
  • No prior cardiac dysfunction, even if presently controlled


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • No prior anthracycline more than 450 mg/m^2

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • No other concurrent cancer therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005033

United States, California
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000
United States, Massachusetts
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Tennessee
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105-2794
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Study Chair: Paul A. Meyers, MD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00005033     History of Changes
Other Study ID Numbers: CDR0000067558  MSKCC-99097  NCI-T98-0083 
Study First Received: April 6, 2000
Last Updated: June 20, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent osteosarcoma

Additional relevant MeSH terms:
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antineoplastic Agents processed this record on October 21, 2016